Biotechnology stocks continued the blood shed on Monday. Shares across the sector tumbled several percentage points, along with exchange traded funds specializing in the industry. This constant downhill slide started last week and is raising questions among investors on whether the sector is finally running out of momentum, following news that U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price tag of its new hepatitis C drug.

More from Video

Video: nLight Shares Surge Following Nasdaq Debut

Video: nLight Shares Surge Following Nasdaq Debut

Too Bearish Too Soon? Your Reality Check from Real Money's Helene Meisler

Too Bearish Too Soon? Your Reality Check from Real Money's Helene Meisler

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: Chipotle Shares Are Probably Done Going Down

Jim Cramer: This Is a Sad Time for Southwest Airlines

Jim Cramer: This Is a Sad Time for Southwest Airlines